DIVI S LABORATORIES LTD vs Sharon Bio-Medicine Ltd

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and Sharon Bio-Medicine Ltd (SHARONBIO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs SHARONBIO on 10 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth10
  • Size & financial health30

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

95.04
P/E ratio
0.00
10.62
P/B ratio
0.00
0.33%
Dividend yield
0.00%
₹96.73
EPS
₹1.60

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
0.00%
22.00%
Return on capital
8.00%
33.00%
EBITDA margin
13.00%
24.32%
Net margin
9.74%

Growth

DIVISLAB takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
4.48%
12.10%
Profit CAGR (3Y) even

Size & financial health

DIVISLAB takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.43L Cr
Market cap
₹0 Cr
₹10,560 Cr
Revenue
₹195 Cr
₹2,568 Cr
Net profit
₹19 Cr
0.00
Debt / equity even
0.00
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
DIVI S LABORATORIES LTD full analysis Sharon Bio-Medicine Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVISLAB vs SHARONBIO: Share Price, Valuation & Which to Buy | DocStoX